Author

K. R. Redinger

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Assay:proteomics· 1 Organism:virus· 1

Frequent Co-Authors

J. Bosch· 2 shared A. G. Thomas· 1 shared A. K. Jayabalan· 1 shared A. Leung· 1 shared A. Malachin· 1 shared B. Murphy· 1 shared B. S. Slusher· 1 shared C. L. King· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

J. Bosch

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Naturally acquired and Vaccine-induced Human Monoclonal Antibodies to Plasmodium vivax Duffy Binding Protein Inhibit Invasion of Plasmodium knowlesi (PvDBPOR) Transgenic Parasites

Q. D. Watson, L. Carias, A. Malachin, K. R. Redinger, J. Bosch, M. Bardelli, R. W. Moon, S. J. Draper, P. A. Zimmerman, C. L. King

This paper evaluates the invasion inhibition of Plasmodium knowlesi transgenic parasites expressing PvDBP by naturally acquired and vaccine-induced human monoclonal antibodies, finding additive and antagonistic effects in combinations.

bioRxiv · Mar 7, 2023 · PreprintMicrobiology

High-throughput Activity Assay for Screening Inhibitors of the SARS-CoV-2 Mac1 Macrodomain

M. A. Dasovich, J. Zhuo, A. G. Thomas, J. A. Goodman, R. L. McPherson, A. K. Jayabalan, V. F. Busa, S.-J. Cheng, B. Murphy, K. R. Redinger, T. Tsukamoto, B. S. Slusher, J. Bosch, J. Wei, A. Leung

The paper develops a high-throughput assay for screening inhibitors of the SARS-CoV-2 Mac1 macrodomain and identifies dasatinib and dihydralazine as inhibitors with selectivity over human MacroD2.

bioRxiv · Oct 7, 2021Biochemistry